Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osocimab monthly subcutaneous dosing in hemodialysis patients with end-stage renal disease
2019-003957-27Phase 2Completed
- Sponsor
- Bayer
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of osocimab in thromboembolism (3 arms), sponsored by Bayer. Primary endpoint: Composite of major and clinically relevant non-major bleeding events. Started May 2020; status: completed.
02
Drugs
osocimab
03
Conditions
thromboembolism
Beyond the preview
Go deeper on 2019-003957-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003957-27.